carboplatin/cisplatin-etoposide

Phase 3Small molecule

carboplatin/cisplatin-etoposide is one of 91 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CancerActive, not recruiting

ChemotherapyNot yet recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

ChemotherapyPreclinical

Not yet recruiting

Competition

Competitive Landscape

141 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

29 2

Tecentriq

Roche

Phase 3

26 3

Camptosar

Pfizer

Phase 3

26 4

Keytruda

Merck & Co.

Phase 3

19 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

97 6

Vepesid

Opdivo

14 8

Tarlatamab-Dznl

Amgen

Phase 3

11 9

Yervoy

Lynparza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Active, not recruiting

Small Cell Lung Cancer

NCT05353257

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, not recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 3·NCT05353257·511 enrolled

Chemotherapy1 trial

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not yet recruiting·SShandong Cancer Hospital and Institute·N/A·NCT06649448·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for carboplatin/cisplatin-etoposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — carboplatin/cisplatin-etoposide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for carboplatin/cisplatin-etoposide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Henlius Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Shanghai Henlius Biotech

carboplatin/cisplatin-etoposide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News